Amakem is a clinical stage ophthalmology company developing innovative new treatments for serious eye conditions. The Company’s lead program is based on AMA0076, a novel, locally-acting Rho kinase (ROCK) inhibitor, in clinical development for the treatment of glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.

Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.